HIMS Stock Analysis: Hims Hers Health | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 7.958m USD | 12M Return: -33.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 555M
Qual. Beats: -1
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hims & Hers Health (HIMS) operates a direct-to-consumer telehealth and wellness platform that connects customers in the U.S., U.K., Canada, Germany, Ireland, France, Spain, and other markets with licensed healthcare professionals. The company sells prescription and non-prescription products under the Hims & Hers brand, spanning general wellness, skincare, sexual health, hair care, supplements, cosmetics, and OTC drugs/devices, alongside laboratory testing and biomarker services. It also offers consultations, post-consultation support, and treatments targeting chronic conditions such as hormone health, weight loss, dermatology, and mental health, distributed through retail partnerships, brick-and-mortar stores, and its own websites and mobile app.
The business runs as a vertically integrated digital health and e-commerce platform, combining telemedicine consultations with proprietary product fulfillment and lab diagnostics under a single consumer brand. As a Health Care Services sub-industry player in the GICS Health Care sector, it sits within the broader direct-to-consumer telehealth segment, which leverages online prescribing and subscription-style ordering to address conditions that have historically been treated through in-person visits.
- GLP-1 weight loss demand fuels subscriber and revenue growth
- FDA scrutiny on compounded semaglutide threatens core revenue stream
- Eli Lilly direct-to-consumer platform intensifies telehealth competition
| Net Income: -13.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -23.18 > 1.0 |
| NWC/Revenue: 18.00% < 20% (prev 9.34%; Δ 8.66% < -1%) |
| CFO/TA 0.13 > 3% & CFO 283.7m > Net Income -13.2m |
| Net Debt (539.1m) to EBITDA (30.1m): 17.94 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (228.4m) vs 12m ago -7.40% < -2% |
| Gross Margin: 67.64% > 18% (prev 77.04%; Δ -9.40% > 0.5%) |
| Asset Turnover: 150.0% > 50% (prev 200.1%; Δ -50.06% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.19 (Total Current Assets 1.05b - Total Current Liabilities 618.8m) / Total Assets 2.27b |
| B: -0.09 (Retained Earnings -205.9m / Total Assets 2.27b) |
| C: -0.02 (EBIT TTM -38.1m / Avg Total Assets 1.58b) |
| D: 0.25 (Book Value of Equity 446.2m / Total Liabilities 1.82b) |
| Altman-Z'' = 1.03 = BB |
| DSRI: 3.0 (Receivables 149.6m/6.94m, Revenue 2.37b/1.78b) |
| GMI: 1.14 (GM 77.04% / 67.64%) |
| AQI: 1.29 (AQ_t 0.33 / AQ_t-1 0.25) |
| SGI: 1.33 (Revenue 2.37b / 1.78b) |
| TATA: -0.13 (NI -13.2m - CFO 283.7m) / TA 2.27b) |
| Beneish M = -0.86 (Cap -4..+1) = D |
As of July 14, 2026, the stock is trading at USD 34.38 with a total of 9,363,499 shares traded. Over the past week, the price has changed by -10.19%, over one month by +13.95%, over three months by +62.55% and over the past year by -33.92%.
Current recommended Stop Loss: 28.60 (which is 16.8% or 2.3 ATR below the current price).
Hims Hers Health has received a consensus analysts rating of 3.46. Therefore, it is recommended to hold HIMS.
- StrongBuy: 4
- Buy: 1
- Hold: 6
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 28.4 | -17.3% |
P/E Forward = 58.8235
P/S = 3.358
P/B = 17.8353
P/EG = 2.1549
Revenue TTM = 2.37b USD
EBIT TTM = -38.1m USD
EBITDA TTM = 30.1m USD
Long Term Debt = 974.1m USD (from longTermDebt, last quarter)
Short Term Debt = 5.58m USD (from shortTermDebt, last quarter)
Debt = 1.29b USD (from shortLongTermDebtTotal, last quarter) + Leases 157.9m
Net Debt = 539.1m USD (calculated: Debt 1.29b - CCE 750.9m)
Enterprise Value = 8.50b USD (7.96b + Debt 1.29b - CCE 750.9m)
Interest Coverage Ratio = unknown (Ebit TTM -38.1m / Interest Expense TTM 0.0)
EV/FCF = 112.0x (Enterprise Value 8.50b / FCF TTM 75.8m)
FCF Yield = 0.89% (FCF TTM 75.8m / Enterprise Value 8.50b)
FCF Margin = 3.20% (FCF TTM 75.8m / Revenue TTM 2.37b)
Net Margin = -0.56% (Net Income TTM -13.2m / Revenue TTM 2.37b)
Gross Margin = 67.64% ((Revenue TTM 2.37b - Cost of Revenue TTM 766.8m) / Revenue TTM)
Gross Margin QoQ = 49.38% (prev 71.94%)
Tobins Q-Ratio = 3.75 (Enterprise Value 8.50b / Total Assets 2.27b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.29b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -30.1m (EBIT -38.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.69 (Total Current Assets 1.05b / Total Current Liabilities 618.8m)
Debt / Equity = 2.89 (Debt 1.29b / totalStockholderEquity, last quarter 446.2m)
Debt / EBITDA = 17.94 (Net Debt 539.1m / EBITDA 30.1m)
Debt / FCF = 7.11 (Net Debt 539.1m / FCF TTM 75.8m)
Total Stockholder Equity = 532.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.84% (Net Income -13.2m / Total Assets 2.27b)
RoE = -2.48% (Net Income TTM -13.2m / Total Stockholder Equity 532.7m)
RoCE = -2.53% (EBIT -38.1m / Capital Employed (Equity 532.7m + L.T.Debt 974.1m))
RoIC = -1.96% (negative operating profit) (NOPAT -30.1m / Invested Capital 1.54b)
WACC = 14.22% (E(7.96b)/V(9.25b) * Re(16.52%) + D(1.29b)/V(9.25b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 16.52% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 59.78 | Cagr: 3.85%
[DCF] Terminal Value 54.56% ; FCFF base≈140.1m ; Y1≈122.9m ; Y5≈99.3m
[DCF] Fair Price = 1.25 (EV 819.0m - Net Debt 539.1m = Equity 279.9m / Shares 223.1m; r=14.22% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.97 | # QB: -1
Revenue Correlation: 99.08 | Revenue CAGR: 63.05% | SUE: -0.54 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+0.00% | Revisions=-77% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.06 | Chg30d=+0.00% | Revisions=-58% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.08 | Chg30d=+0.00% | Revisions=-75% | GrowthEPS=-115.7% | GrowthRev=+34.3%
EPS next Year (2027-12-31): EPS=0.67 | Chg30d=+0.00% | Revisions=-58% | GrowthEPS=+937.5% | GrowthRev=+41.6%
[Analyst] Revisions Ratio: -82% (up=2, down=35)